These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 1654139)

  • 1. Tetracyclines inhibit connective tissue breakdown: new therapeutic implications for an old family of drugs.
    Golub LM; Ramamurthy NS; McNamara TF; Greenwald RA; Rifkin BR
    Crit Rev Oral Biol Med; 1991; 2(3):297-321. PubMed ID: 1654139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Host modulation with tetracyclines and their chemically modified analogues.
    Golub LM; Suomalainen K; Sorsa T
    Curr Opin Dent; 1992 Mar; 2():80-90. PubMed ID: 1325849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms.
    Golub LM; Lee HM; Ryan ME; Giannobile WV; Payne J; Sorsa T
    Adv Dent Res; 1998 Nov; 12(2):12-26. PubMed ID: 9972117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The nonantimicrobial properties of tetracycline for the treatment of periodontal disease.
    Vernillo AT; Ramamurthy NS; Golub LM; Rifkin BR
    Curr Opin Periodontol; 1994; ():111-8. PubMed ID: 8032451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blocking periodontal disease progression by inhibiting tissue-destructive enzymes: a potential therapeutic role for tetracyclines and their chemically-modified analogs.
    Rifkin BR; Vernillo AT; Golub LM
    J Periodontol; 1993 Aug; 64(8 Suppl):819-27. PubMed ID: 8410621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tetracyclines inhibit tissue collagenase activity. A new mechanism in the treatment of periodontal disease.
    Golub LM; Ramamurthy N; McNamara TF; Gomes B; Wolff M; Casino A; Kapoor A; Zambon J; Ciancio S; Schneir M
    J Periodontal Res; 1984 Nov; 19(6):651-5. PubMed ID: 6098638
    [No Abstract]   [Full Text] [Related]  

  • 7. Tetracycline inhibition and the cellular source of collagenase in gingival crevicular fluid in different periodontal diseases. A review article.
    Ingman T; Sorsa T; Suomalainen K; Halinen S; Lindy O; Lauhio A; Saari H; Konttinen YT; Golub LM
    J Periodontol; 1993 Feb; 64(2):82-8. PubMed ID: 8433257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A non-antibacterial chemically-modified tetracycline inhibits mammalian collagenase activity.
    Golub LM; McNamara TF; D'Angelo G; Greenwald RA; Ramamurthy NS
    J Dent Res; 1987 Aug; 66(8):1310-4. PubMed ID: 3040832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blocking Periodontal Disease Progression by Inhibiting Tissue-Destructive Enzymes: A Potential Therapeutic Role for Tetracyclines and Their Chemically-Modified Analogs.
    Rifkin BR; Vernillo AT; Golub LM
    J Periodontol; 1993 Aug; 64 Suppl 8S():819-827. PubMed ID: 29539753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Introduction and background.
    Golub LM
    Pharmacol Res; 2011 Feb; 63(2):99-101. PubMed ID: 20937387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimicrobial and non-antimicrobial tetracyclines in human cancer trials.
    Richards C; Pantanowitz L; Dezube BJ
    Pharmacol Res; 2011 Feb; 63(2):151-6. PubMed ID: 20951804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tetracyclines inhibit tissue collagenases. Effects of ingested low-dose and local delivery systems.
    Golub LM; Goodson JM; Lee HM; Vidal AM; McNamara TF; Ramamurthy NS
    J Periodontol; 1985 Nov; 56(11 Suppl):93-7. PubMed ID: 3001266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Chemically Modified Tetracyclines in the Management of Periodontal Diseases: A Review.
    Ghangurde AA; Ganji KK; Bhongade ML; Sehdev B
    Drug Res (Stuttg); 2017 May; 67(5):258-265. PubMed ID: 28268238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of matrix metalloproteinase-mediated periodontal bone loss in rats: a comparison of 6 chemically modified tetracyclines.
    Ramamurthy NS; Rifkin BR; Greenwald RA; Xu JW; Liu Y; Turner G; Golub LM; Vernillo AT
    J Periodontol; 2002 Jul; 73(7):726-34. PubMed ID: 12146531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treating periodontal diseases by blocking tissue-destructive enzymes.
    Golub LM; Wolff M; Roberts S; Lee HM; Leung M; Payonk GS
    J Am Dent Assoc; 1994 Feb; 125(2):163-9; discussion 169-71. PubMed ID: 8113524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Matrix metalloproteinases and their inhibition in periodontal treatment.
    Ryan ME; Ramamurthy S; Golub LM
    Curr Opin Periodontol; 1996; 3():85-96. PubMed ID: 8624573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Excessive matrix metalloproteinase activity in diabetes: inhibition by tetracycline analogues with zinc reactivity.
    Ryan ME; Usman A; Ramamurthy NS; Golub LM; Greenwald RA
    Curr Med Chem; 2001 Feb; 8(3):305-16. PubMed ID: 11172685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tetracyclines inhibit human synovial collagenase in vivo and in vitro.
    Greenwald RA; Golub LM; Lavietes B; Ramamurthy NS; Gruber B; Laskin RS; McNamara TF
    J Rheumatol; 1987 Feb; 14(1):28-32. PubMed ID: 3033237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Periodontal therapeutics: Current host-modulation agents and future directions.
    Golub LM; Lee HM
    Periodontol 2000; 2020 Feb; 82(1):186-204. PubMed ID: 31850625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-antibacterial tetracycline formulations: host-modulators in the treatment of periodontitis and relevant systemic diseases.
    Golub LM; Elburki MS; Walker C; Ryan M; Sorsa T; Tenenbaum H; Goldberg M; Wolff M; Gu Y
    Int Dent J; 2016 Jun; 66(3):127-35. PubMed ID: 27009489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.